Blood Res 2017; 52(2): 95-99
Dapsone therapy for refractory immune thrombocytopenia patients: a case series
Ji Yun Lee1, Jeong-Ok Lee1, Joo Young Jung2,#*, and Soo-Mee Bang1,#

1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

2Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.

Correspondence to: Soo-Mee Bang, M.D., Ph.D. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam 13620, Korea.
Received: December 10, 2016; Revised: March 1, 2017; Accepted: April 11, 2017; Published online: June 22, 2017.
© The Korean Journal of Hematology. All rights reserved.



Dapsone has been recommended as a second-line immunosuppressive agent for patients with immune thrombocytopenia (ITP).


We retrospectively analyzed the efficacy and safety of dapsone therapy in patients with ITP.


Nine ITP patients were treated with dapsone at a dose of 50?100 mg/day between May 2013 and March 2016. All patients were refractory to multiple previous treatments, with a median of 7 agents (range, 4?8), and 3 patients had undergone a previous splenectomy. The median pre-treatment platelet count was 4×109/L (range, 3?27×109/L). Only 1 patient (11.1%) responded to dapsone therapy. No severe adverse events were observed, except for 1 case of dapsone hypersensitivity syndrome.


Although dapsone is still useful for some patients, it may be ineffective in heavily pretreated patients with profound thrombocytopenia.

Keywords: Immune thrombocytopenia, Dapsone, Efficacy, Toxicity


This Article

Current Issue


Indexed/Covered by

Today : 118  /
Total : 201,872